



Fiscal Note

Legislative Council Staff

Nonpartisan Services for Colorado's Legislature

HB 26-1325: NATURAL MEDICINE

Prime Sponsors:

Rep. Caldwell; Feret
Sen. Ball

Fiscal Analyst:

Aaron Carpenter, 303-866-4918
aaron.carpenter@coleg.gov

Published for: House Appropriations**Drafting number:** LLS 26-0782**Version:** First Revised Note**Date:** April 1, 2026

Fiscal note status: The revised fiscal note reflects the introduced bill, as amended by the House Health and Human Services committee.

Summary Information

Overview. The bill creates a pilot program on the safety and effectiveness of using ibogaine to treat mental health conditions and makes changes on facilitator liability and the Natural Medicine Advisory Board.

Types of impacts. The bill is projected to affect the following areas on an ongoing basis:

- State Revenue
- State Expenditures

Appropriations. For FY 2026-27, the bill requires an appropriation of \$132,250 to the Behavioral Health Administration.

Table 1
State Fiscal Impacts

Type of Impact	Budget Year FY 2026-27	Out Year FY 2027-28
State Revenue	\$0	\$0
State Expenditures	\$151,536	\$154,670
Transferred Funds	\$0	\$0
Change in TABOR Refunds	\$0	\$0
Change in State FTE	0.8 FTE	1.0 FTE

Fund sources for these impacts are shown in the tables below.

**Table 1A
State Expenditures**

Fund Source	Budget Year FY 2026-27	Out Year FY 2027-28
General Fund	\$132,250	\$130,563
Cash Funds	\$0	\$0
Federal Funds	\$0	\$0
Centrally Appropriated	\$19,285	\$24,107
Total Expenditures	\$151,536	\$154,670
Total FTE	0.8 FTE	1.0 FTE

Summary of Legislation

The bill requires the Behavioral Health Administration (BHA) to create a pilot program on the administration of ibogaine, makes changes to the Natural Medicine Advisory Board, updates protections for facilitators, establishes an order of prioritization for natural medicine licenses, and grants the Department of Revenue (DOR) authority to establish rules on the administration of ibogaine.

Pilot Program

Contingent on federal approval, the bill establishes a pilot program in the BHA to support research on the safety and effectiveness of using ibogaine to treat mental health conditions and substance use disorders. The program may approve up to five pilot sites based on the recommendations of a review committee. The bill requires the BHA create a process to solicit and select pilot sites, assist pilot sites to complete and submit an investigational new drug application with the federal government and to consider whether to obtain federal research program status. The bill also outlines requirements to become a pilot site, the rules for the program, and reporting requirements of the BHA and pilot sites. Finally, the bill allows the BHA to accept gifts, grants, and donations and to deposit them in the newly created Ibogaine Research Pilot Program Cash Fund.

Definition of Ibogaine

The bill adds ibogaine derived from a semi-synthetic process approved by the Natural Medicine Advisory Board to the definition of natural medicine in the Natural Medicine Act.

Natural Medicine Advisory Board

The bill removes the requirement that members of the Natural Medicine Advisory Board be approved by the Senate, and revises the expertise and experience requirements to apply equally to all 15 board members. The bill also allows the Governor to remove a member if it is determined that changes to the board's composition are necessary to ensure the board possesses the required expertise. The board may make recommendations of additional genera or species of plants that may be cultivated and manufactured to create semi-synthetic ibogaine.

Facilitator Liability

The bill makes facilitators liable for money damages in a malpractice action for a physical or psychological injury only if the injury was the direct result of intentional misconduct, gross negligence, or a deviation from the standards of practice. The provision does not apply to administrative proceedings.

Facilitator Regulation

The bill requires the Department of Regulatory Agencies (DORA) to adopt rules on the requirements for the use and administration of ibogaine to include requirements for medical prescreening, monitoring, oversight, and aftercare.

Site Regulation

The bill requires the Department of Revenue (DOR) to prioritize licenses for natural medicine facilities in the following order:

- applicants who participate in the pilot program;
- applicants who have established residency in Colorado; and
- applicants who demonstrate priority review status as established by rule.

Under current law, additional substances can be considered natural medicines if recommended by the Natural Medicine Advisory Board and approved by the executive director of the DOR and DORA. The bill requires that the DOR have sufficient funding to finance the program before a substance is added. Once sufficient funding is secured, DOR, the board, DORA, the BHA, and the Department of Public Health and Environment must determine the program scope for implementation.

The bill permits the DOR to enact rules to establish different application fees based on the type of natural medicine. Licensees must establish a plan that benefits indigenous communities before cultivating, manufacturing, testing, dispensing, or administering ibogaine. The DOR may collect gifts, grants, and donations for this purpose.

Background

Ibogaine is a psychoactive molecule that is derived from plants like the iboga plant, which is a shrub native to central Africa. The personal use and possession of ibogaine was decriminalized as a part of Proposition 122. Current law requires the Natural Medicine Advisory Board to study whether ibogaine should be included as part of the Natural Medicine Act and administered in regulated healing centers. In 2025, the [board recommended](#) that ibogaine be included in the definition of natural medicine, subject to the acquisition of the medicine through the Nagoya Protocol. As a result of this recommendation, ibogaine may be included as a natural medicine upon approval of the executive director of DOR.

State Revenue

The bill may increase state revenue from gifts, grants, and donations, and from potential licensing fees, as described below.

Gifts, Grants, and Donations

Starting in FY 2026-27, the bill increases state cash fund revenue to the extent additional gifts, grants, and donations are received. At the time of the writing, additional gifts, grants, and donations have not been identified and are assumed to be minimal. Gifts, grants, and donations are not subject to the state's TABOR limit.

Ibogaine Pilot Program Licensing

The bill may increase revenue to the DOR to the extent DOR decides to require an additional license for the administration of ibogaine for pilot program sites. Due to the small number of allowed pilot program sites, and the permissive nature of the licensing fee, the fiscal note assumes licensing costs will be paid from the General Fund.

State Expenditures

The bill increases state expenditures by \$152,000 in FY 2026-27 and \$155,000 in FY 2027-28 and ongoing for the duration of the pilot program. These costs, paid from the General Fund, will be incurred in the Behavioral Health Administration, as shown in Table 2 and described in the sections below. The bill will also increase workload in the Department of Regulatory Agencies and the Department of Revenue.

Behavioral Health Administration

The BHA will have staff and contract service costs beginning in FY 2026-27 to implement the bill.

Staff

The BHA requires 1.0 FTE to oversee the pilot program. Duties will include rulemaking oversight and coordination, seeking and reviewing applications for the pilot program, coordinating with necessary stakeholders including the federal government, providing support and technical assistance to pilot sites, and to provide oversight to contracts for evaluation. Standard operating and capital outlay costs are included, and staff are prorated for a September 1 start date.

Contract Services

The BHA will contract for consultation from external experts on the use of ibogaine, clinical research process, and to evaluate the impact of the program. Contract costs are estimated at \$104 per hour at 400 hours in FY 2026-27 and 250 hours in FY 2027-28. Costs in the first year are higher due to additional hours for consultation as the program is established.

Table 2
State Expenditures
Behavioral Health Administration

Cost Component	Budget Year FY 2026-27	Out Year FY 2027-28
Personal Services	\$82,626	\$103,283
Operating Expenses	\$1,024	\$1,280
Capital Outlay Costs	\$7,000	\$0
Legal Services	\$41,600	\$26,000
Centrally Appropriated Costs	\$19,285	\$24,107
Total Costs	\$151,535	\$154,670
Total FTE	0.8 FTE	1.0 FTE

Department of Revenue

The bill requires that the DOR receive sufficient funds before regulation of a recommended natural medicine may begin. The fiscal note assumes that if a natural medicine is recommended for regulation, the DOR will request funding through the annual budget process. For informational purposes, it is estimated that \$520,000 and 5.0 FTE is required to create a regulatory program for ibogaine.

Department of Regulatory Agencies

The bill increases workload in the Department of Regulatory Agencies to make necessary rule and guideline changes for facilitator, clinical facilitator, and training license types. This workload can be accomplished within existing appropriations.

Centrally Appropriated Costs

Pursuant to a Joint Budget Committee policy, certain costs associated with this bill are addressed through the annual budget process and centrally appropriated in the Long Bill or supplemental appropriations bills, rather than in this bill. These costs, which may include employee insurance, supplemental employee retirement payments, indirect cost assessments, and other costs, are shown in the tables above.

Effective Date

The bill takes effect 90 days following adjournment of the General Assembly sine die, assuming no referendum petition is filed.

State Appropriations

For FY 2026-27, the bill requires a General Fund appropriation of \$132,250 to the Behavioral Health Administration, and 0.9 FTE.

State and Local Government Contacts

Behavioral Health Administration

Revenue

Law

The revenue and expenditure impacts in this fiscal note represent changes from current law under the bill for each fiscal year. For additional information about fiscal notes, please visit the [General Assembly website](#).